Metallomix is leveraging cutting-edge science to develop new therapies that address critical gaps in treatment of neurological disorders, ensuring clinically derisked development and streamlined regulatory approval pathways.
| Indication | Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | Market |
|---|---|---|---|---|---|---|
Parkinson's Disease | ||||||
Alzheimer's Disease | ||||||
Lewy Body Dementia | ||||||
Friedreich's Ataxia | ||||||
Amyotrophic Lateral Sclerosis | ||||||
Multiple sclerosis | ||||||
Huntington's Disease | ||||||
| Parkinson's Disease | |||||
| Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | Market |
| Alzheimer's Disease | |||||
| Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | Market |
| Lewy Body Dementia | |||||
| Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | Market |
| Friedreich's Ataxia | |||||
| Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | Market |
| Amyotrophic Lateral Sclerosis | |||||
| Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | Market |
| Multiple sclerosis | |||||
| Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | Market |
| Huntington's Disease | |||||
| Discovery | Preclinical | Phase 1 | Phase 2 | Phase 3 | Market |
Parkinson's disease (PD) is a progressive neurodegenerative brain disorder that causes unintended and/or uncontrollable movements, such as shaking, stiffness, and difficulty with balance, coordination, walking, and talking. Our leading drug candidate, KLS1.2-1 is designed to bring therapeutic effect of the isotope selective modulation therapy to people suffering from Parkinson's Disease. The drug is aimed to improve both, cognitive and motor functions in the patients in early to moderate symptomatic stages, and is preparing for Phase II clinical trial, which is presently pending a regulatory adjustment.
Alzheimer’s disease (AD) is a progressive neurodegenerative brain disorder that slowly destroys memory and cognition and, eventually, the ability to carry out even the simplest daily tasks. Our drug candidate, KLS1.2-2, is designed to bring therapeutic effect of the isotope selective modulation therapy to people suffering from Alzheimer's Disease. In preclinical studies, KLS1.2-2 shown strong data to improve both, cognitive and memory functions in the patients in all symptomatic stages. KLS1.2-2 is presently in await of Phase I clinical trial, for which we expect topline data by June 2024.
Lewy body dementia (LBD) is the second most common type of progressive dementia after Alzheimer's disease. It is characterized by abnormal aggregation of a protein called alpha-synuclein, known as Lewy bodies, in the brain. This aggregation gradually affects brain regions involved in thinking, memory, and movement, leading to a decline in mental abilities that worsens over time. We design our flagship drug candidate, KLS1.2-3, to bring longer-lasting symptomatic relief to LBD patients. KLS1 is aimed to improve cognitive and motor functions, as well as autonomic nervous system function, in the patients with early to moderate symptomatic stages.
Presently in discovery stage.
Presently in discovery stage.
Presently in discovery stage.
Presently in conceptual stage.
